Arcutis Biotherapeutics: ZORYVE’s Multi-Indication Momentum as a Catalyst for Sustained Dermatology Leadership
Arcutis Biotherapeutics Inc. (NASDAQ: ARQT), a commercial-stage biopharmaceutical firm targeted on immuno-dermatology, not too long ago unveiled its third-quarter 2025 ...